Get the Stockscreener App
13.99
2.72%
0.37
After Hours:
13.99
Cadrenal Therapeutics Inc stock is traded at $13.99, with a volume of 49,125.
It is up +2.72% in the last 24 hours and up +6.39% over the past month.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
See More
Previous Close:
$13.62
Open:
$14.07
24h Volume:
49,125
Relative Volume:
1.76
Market Cap:
$28.64M
Revenue:
-
Net Income/Loss:
$-4.85M
P/E Ratio:
-45.13
EPS:
-0.31
Net Cash Flow:
$-3.95M
1W Performance:
+3.40%
1M Performance:
+6.39%
6M Performance:
-6.73%
1Y Performance:
+3.63%
1-Day Range:
$13.91
$14.50
1-Week Range:
$13.48
$14.50
52-Week Range:
$8.74
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Name
Cadrenal Therapeutics Inc
Sector
Industry
Phone
904-300-0701
Address
822 A1A NORTH, PONTE VEDRA
Compare CVKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
13.99 | 27.88M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-23 | Initiated | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Stock (CVKD) Latest News
What institutional flow reveals about Cadrenal Therapeutics Inc.2025 Market Outlook & Long Hold Capital Preservation Tips - newser.com
Is Cadrenal Therapeutics Inc a good long term investmentProtective Put Strategies & Unlock Long-Term Capital Growth Ideas - earlytimes.in
Applying chart zones and confluence areas to Cadrenal Therapeutics Inc.2025 Buyback Activity & Entry Point Confirmation Alerts - newser.com
Published on: 2025-10-13 02:03:23 - newser.com
How to escape a deep drawdown in Cadrenal Therapeutics Inc.July 2025 Retail & Free High Return Stock Watch Alerts - newser.com
Can Cadrenal Therapeutics Inc. recover in the next quarterMarket Performance Summary & Accurate Intraday Trading Signals - newser.com
What does recent volatility data suggest for Cadrenal Therapeutics Inc.Earnings Risk Report & Consistent Return Strategy Ideas - newser.com
Visual trend scoring systems applied to Cadrenal Therapeutics Inc.Long Setup & Weekly Setup with ROI Potential - newser.com
Cadrenal Therapeutics Inc. stock trend outlook and recovery pathJuly 2025 Update & Expert Curated Trade Ideas - newser.com
Backtesting results for Cadrenal Therapeutics Inc. trading strategiesBreakout Watch & Real-Time Chart Pattern Alerts - newser.com
Custom watchlist performance reports with Cadrenal Therapeutics Inc.2025 Price Momentum & Consistent Income Trade Ideas - newser.com
Cadrenal therapeutics CFO Szot sells $1496 in shares - Investing.com
Cadrenal Therapeutics Inc. stock daily chart insightsWeekly Volume Report & Community Shared Stock Ideas - newser.com
Can Cadrenal Therapeutics Inc. stock beat market expectations this quarterSwing Trade & Free Expert Verified Stock Movement Alerts - newser.com
Can Cadrenal Therapeutics Inc. stock sustain institutional interestMarket Trend Report & Risk Adjusted Buy/Sell Alerts - newser.com
Cadrenal Therapeutics Expands Pipeline With Portfolio Acquisition Worth Up To $15 Million - MSN
Insider Sell: Matthew Szot Sells Shares of Cadrenal Therapeutics Inc (CVKD) - GuruFocus
CVKD: Acquires Factor XIa Inhibitors - Smartkarma
CVKD: Acquires Factor XIa Inhibitors… - Yahoo Finance
Will a bounce in Cadrenal Therapeutics Inc. offer an exitWeekly Investment Recap & Consistent Return Investment Signals - newser.com
Cadrenal Therapeutics Inc Stock Analysis and ForecastVolume Analysis Techniques & Hidden Gems with Outstanding Profit Margins - earlytimes.in
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - GlobeNewswire
Anticoagulation Therapy Biotech Cadrenal Therapeutics to Showcase Pipeline at Lytham Investor Conference - Stock Titan
Published on: 2025-09-30 10:26:28 - earlytimes.in
Multi factor analysis applied to Cadrenal Therapeutics Inc.2025 Support & Resistance & Daily Profit Maximizing Trade Tips - newser.com
What analysts say about Cadrenal Therapeutics Inc stockLow Beta Stocks & High Return Trading Ideas - earlytimes.in
Cadrenal therapeutics (CVKD) CEO Pham sells $131,779 in stock By Investing.com - Investing.com Australia
Cadrenal Therapeutics Inc Stock (CVKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):